41 Quotes by Jan Wald

It underscores why they were so bent on doing the Guidant deal.

They were being nickel-and-dimed by J&J. They had to get out of that loop.

In investors' minds, they've been accused of being a one-trick pony, and they don't have a pipeline. If they get Guidant, they answer both those questions. They'll be in one of the fastest-growing medical devices markets, for implantable defibrillators, and they'll have Guidant's pipeline.

If you're a Guidant shareholder, you have to ask yourself whether you'd rather hold Boston paper or Johnson & Johnson paper. I would rather hold Boston, because I'm holding Guidant for growth.

Integration is going full-speed ahead. I don't think they would be concerned by a two-week delay in closing the deal, even though there's an interest payment.

I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.

If the relationship has been adversarial, the FDA, we believe, would not be as accommodating, even in speech.

I think of all the pieces, it's pharmaceuticals that are hurting them the most.

I certainly think it could be a stand-alone company. I'm not certain it should be.